A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Trial Profile

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Abatacept (Primary) ; Abatacept (Primary) ; Infliximab (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Tocilizumab (Primary) ; Diphenhydramine; Leflunomide; Methotrexate; Methylprednisolone; Paracetamol
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Acronyms BIOBIO
  • Most Recent Events

    • 14 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 19 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
    • 16 Jan 2017 Last checked against European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top